CureVac Announces Decision Of German Federal Patent Court In Broad Patent Litigation With BioNTech SE
Portfolio Pulse from Benzinga Newsdesk
CureVac N.V. announced that the German Federal Patent Court denied the validity of its patent EP 1 857 122 B1 after a nullity action by BioNTech SE. This decision does not impact other ongoing litigation in Germany involving seven other CureVac intellectual property rights. CureVac plans to appeal the decision at the German Federal Court of Justice. The company remains confident in its intellectual property portfolio and its contributions to mRNA COVID-19 vaccines. The scheduled ruling on infringement of the patent by BioNTech's Comirnaty is likely to be postponed.
December 19, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CureVac's patent was invalidated by the German Federal Patent Court, but the company plans to appeal. This legal setback could negatively impact investor sentiment in the short term.
The invalidation of a key patent could be seen as a negative development for CureVac, potentially affecting its ability to protect its mRNA technology and its competitive position. However, the company's intention to appeal and the ongoing litigation over other patents provide some mitigation.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90
NEUTRAL IMPACT
The legal dispute between CureVac and BioNTech, both German companies, may have minor implications for the iShares MSCI Germany ETF, but the direct impact is likely limited.
While the dispute is between two notable German companies in the ETF, the direct impact on the broader German market and the ETF is likely to be minimal, as the ETF is diversified across various sectors and companies.
CONFIDENCE 60
IMPORTANCE 20
RELEVANCE 30
POSITIVE IMPACT
BioNTech SE's successful nullity action against CureVac's patent may be viewed positively, but the outcome of the ongoing litigation over other patents remains uncertain.
BioNTech's success in the nullity action could be seen as a victory, potentially strengthening its position in the mRNA vaccine market. However, the ongoing litigation over other patents and the possibility of an appeal introduce uncertainty that tempers the potential impact.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70